DrugPatentWatch Database Preview
Drugs in Development Information for Ibodutant
» See Plans and Pricing
What is the development status for investigational drug Ibodutant?
Ibodutant is an investigational drug.
There have been 5 clinical trials for Ibodutant.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2015.
The most common disease conditions in clinical trials are Syndrome, Irritable Bowel Syndrome, and Diarrhea. The leading clinical trial sponsors are Menarini Group and [disabled in preview].
There are three US patents protecting this investigational drug and one hundred and seven international patents.
Summary for Ibodutant
| US Patents | 3 |
| International Patents | 107 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 34 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2015-10-01) |
| Vendors | 13 |
Recent Clinical Trials for Ibodutant
| Title | Sponsor | Phase |
|---|---|---|
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
| 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
Clinical Trial Summary for Ibodutant
Top disease conditions for Ibodutant
Top clinical trial sponsors for Ibodutant
US Patents for Ibodutant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibodutant | Start Trial | Linear basic compounds having NK-2 antagonist activity and formulations thereof | Menarini Ricerche S.P.A. (Pomezia, IT) | Start Trial |
| Ibodutant | Start Trial | Pharmaceutical compositions based on NK2 antagonists for pediatric use | Laboratori Guidotti S.p.A. (Pisa, IT) | Start Trial |
| Ibodutant | Start Trial | Process for the preparation of ibodutant (MEN15596) and related intermediates | Malesci Istituto Farmacobiologico S.p.A. (Bagno A Ripoli, IT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibodutant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibodutant | Argentina | AR037044 | 2021-10-29 | Start Trial |
| Ibodutant | Austria | AT339439 | 2021-10-29 | Start Trial |
| Ibodutant | Australia | AU2002351794 | 2021-10-29 | Start Trial |
| Ibodutant | Brazil | BR0213574 | 2021-10-29 | Start Trial |
| Ibodutant | Brazil | BRPI0213574 | 2021-10-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
